Zimmer Partners’s Tourmaline Bio TRML Stock Holding History

Zimmer Partners’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,333	Closed	-$343K	–	191
2021 Q2	$343K	Buy	+2,333	New	+$357K	﹤0.01%	165

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Zimmer Partners's TRML Position: Q3 2021 in Review

Zimmer Partners sold out of Tourmaline Bio (TRML) in Q3 2021, closing a stake of 2,333 shares — an estimated $343K sold.

Zimmer Partners first reported a position in TRML in Q2 2021 and held it in 1 quarter. The position peaked at $343K in Q2 2021. 48 funds tracked by Wall St. Rank hold TRML as of Q3 2021.

Zimmer Partners reported no remaining Tourmaline Bio position as of Q3 2021 after selling out during the quarter.
Zimmer Partners sold 2,333 Tourmaline Bio shares in Q3 2021, an estimated $343K.
Zimmer Partners first reported a position in Tourmaline Bio in Q2 2021 and held it in 1 quarter.
Zimmer Partners's Tourmaline Bio position peaked at $343K in Q2 2021.
48 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2021.

Based on Zimmer Partners's 13F filing for Q3 2021, filed 15 Nov 2021.